Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting

Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting

Abstract Background To compare the benefits and explore the cause of acquired resistance of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and its combination with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients harboring EGFR mutation in a real-life setti...

Full description

Bibliographic Details
Main Authors: Qianqian Wang, Wen Gao, Fangyan Gao, Shidai Jin, Tianyu Qu, Fan Lin, Chen Zhang, Jingya Zhang, Zhihong Zhang, Liang Chen, Renhua Guo
Format: Article
Language:English
Published: BMC 2021-05-01
Series:BMC Cancer
Subjects:
Non-small cell lung cancer
First-line treatment
EGFR-TKI
Chemotherapy
Acquired resistance
Online Access:https://doi.org/10.1186/s12885-021-08291-9

Internet

https://doi.org/10.1186/s12885-021-08291-9

Similar Items